Skip to main content

Table 3 Comparison of baseline and follow-up metabolic parameters.

From: A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients

  Baseline Follow-up Follow-up
  (n = 90) (all subjects, n = 90) (antipsychotic-treated subjects, n = 83)
BMI, kg/m2 29.2 (5.1) 29.9 (4.9)* 29.8 (4.9)*
BMI category    
Underweight (%) 1.1 2.2 2.4
Normal (%) 16.7 10.0 8.4
Overweight (%) 34.4 43.3* 44.6*
Obese (%) 47.8 44.4 44.6
Waist Circumference, cm 94.6 (13.2) 96.2 (13.1) † 96.2 (13.0) †
Fasting blood glucose, mmol/l 5.6 (2.4) 5.5 (1.4) 5.5 (1.4)
HbA 1c, % 5.4 (1.2) 5.6 (1.0) 5.6 (1.0)
Serum insulin, MU/l 12.9 (13.4) 11.1 (8.1) 11.1 (8.2)
HOMA B, % 106.3 (38.6) 98.8 (38.8) † 99.7 (39.7)
HOMA S, % 95.9 (60.5) 98.6 (55.6) 98.4 (55.6)
HOMA IR, % 1.8 (1.7) 1.5 (1.1) † 1.5 (1.1)
Glycaemic status    
Normoglycaemia, % 86.7 85.6 86.8
Impaired fasting glucose, % 6.7 8.9 7.2
Diabetes Mellitus, % 6.7 5.6 6.0
Total Cholesterol, mmol/l 5.6 (1.2) 5.7 (1.5) 5.7 (1.5)
Raised total cholesterol, % 27.8 28.9 31.3
HDL-Cholesterol, mmol/l 1.3 (0.4) 1.3 (0.4) 1.3 (0.4)
LDL-Cholesterol, mmol/l 3.2 (0.9) 3.3 (1.1) 3.3 (1.3)
Triglycerides, mean (range), mmol/l 2.3 (0.6–8.4) 2.1 (0.5–6.9) 2.1 (0.5–6.9)
Raised total triglycerides, % 53.3 51.1 53.0
Lipid-lowering therapy, % 4.4 7.8 7.2
  1. * p < 0.005 baseline vs follow-up; † p < 0.05 baseline vs follow-up
  2. Data are means ± SD unless otherwise stated.